Uses for anti-malarial therapeutic agents

A kind of use and drug technology, applied in the field of treating colds and hydroxychloroquine, can solve the problems of no effective antiviral compounds for viral infection, no vaccines, etc.

Inactive Publication Date: 2006-12-13
APT PHARMA INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0021] However, to date, there are no clinically effective antiviral compounds for the treatment and/or pre

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uses for anti-malarial therapeutic agents
  • Uses for anti-malarial therapeutic agents
  • Uses for anti-malarial therapeutic agents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031] The present inventors have discovered that antimalarial compounds, most precisely antimalarial compounds including quinolines, have the ability to:

[0032] 1] Inhibition of viral infection of airway epithelial cells by rhinoviruses, adenoviruses, human coronaviruses and influenza viruses by changing the pH of entering vesicles and by reducing the expression of rhinovirus cell surface receptor ICAM-1;

[0033] 2] abolishes the effect of symptom-causing pro-inflammatory chemokines from rhinovirus-infected epithelial cells; and

[0034] 3] Inhibit the production of inflammatory mediators by leukocytes recruited to the site of viral inflammation.

[0035] The present inventors have discovered that said antimalarial compounds are most effective in treating or preventing viral infections when administered by organ-targeted delivery. The term "organ-targeted delivery" as used herein refers to direct administration to a virus-infected organ. Viral infections that cause colds...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention is directed to the use of anti-malarial compound for the treatment and prophylaxis of infections by adenovirus or rhinovirus.

Description

field of invention [0001] The present invention relates to a method for treating viral respiratory tract infections in mammals, the method comprising administering to the mammals an antiviral effective amount of an antimalarial compound, such as hydroxychloroquine (HCQ), by targeted organ delivery. The present invention also relates to the use of said antimalarial compounds in the treatment of colds. Background of the invention [0002] "Most nasopharyngeal infections are caused by viruses and produce signs and symptoms collectively known as colds. About 40-50% of colds are caused by the rhinovirus (RV) group." (Schaechter M, Engeleberg N, Eisenstein B, Medoff G, Mechanisms of Microbial Disease (3rd edition). Lippincott, Williams, and Williams. Philadelphia, 1999, p. 550). Other important viral pathogens include human coronaviruses, adenoviruses and influenza viruses. Recent evidence also suggests that rhinovirus infection is an important precipitating factor in the exacer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/47C07D215/40A61K9/00A61K9/06A61K9/08A61K9/107A61K9/12A61K31/4706A61K31/4709A61K31/473A61P11/00A61P27/02A61P31/12A61P33/02C07D219/12C07D401/06
CPCA61K31/47A61K31/4709A61K31/473A61K31/4706A61K9/0073A61P11/00A61P27/02A61P31/12A61P33/02Y02A50/30
Inventor 劳伦·夏鲁
Owner APT PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap